The prevalence of metabolic dysfunction, associated steatotic liver disease previously described as nonalcoholic fatty liver disease, continues to rise globally.
#MASLD#NAFLD#liversteatosis#gutmicrobiome#gutliveraxis
Article by Salim Maher, et. al
https://t.co/WgIOsQzaQ0
Drug-induced liver injury continues to be a major concern in clinical practice, thus necessitating a need for novel therapeutic approaches to alleviate its impact on hepatic function.
#druginducedliverinjury#polyphenols
Article by Namya Sethi, et. al
https://t.co/lItWs2yRnq
Read SLD Issue 44.4 on "Steatotic Liver Disease: Pathogenesis, Biomarkers and Novel Targets for Therapy" today! https://t.co/6m1Nr9oa5Q
🔹Management of Portal Thrombosis & ACLF
🔹Role of Complement and the Microbiome
🔹Humanized Mice Livers
@rabataller
@DrPMonga
Rodents are commonly employed to model human liver conditions, although species differences can restrict their translational relevance. Read more about overcoming some of these limitations here "Mice Engrafted with Human Liver Cells" from Ype P. de Jong.
https://t.co/Glf2UQmJZM
Portal vein thrombosis (PVT) is one of the common complications of cirrhosis.
#thrombosis#portalhypertension#anticoagulants
Find out more about "Management of Portal vein Thrombosis in Cirrhosis" in the article from Babu Lal Meena and Shiv Kumar Sarin
https://t.co/rl0G1kzVWc
Find out more about noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article by Monica A. Tincopa and Rohit Loomba
#NAFLD#MASLD#MASH#noninvasivetests
https://t.co/rcKsKQHDGF
Read SLD Issue 44.3 on "Steatotic Liver Disease: Pathogenesis, Biomarkers & Novel Targets for Therapy" today! https://t.co/bmdBHoOPiJ
🔹Management of Gallstones
🔹HNF4alpha in Liver Cancer
🔹Necrotic Liver Resolution & Role of Extracellular Matrix
@rabataller
@DrPMonga
Stronger together with an overcoming resistance to immune checkpoint blockade in liver cancer with combination therapy? #hepatocellularcarcinoma#checkpointinhibitors#resistance
Get the answers in the article by Wiebke Werner, et. al
https://t.co/eaWbeFQ8KC
Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives by Caiyi Cherry Li, et. al.
Read more about the success of immunotherapy
#livercancer#immunotherapy#tumorheterogeneity
https://t.co/1Q2IPkBGbT
Read Issue 44.2 "Heterogeneity in Liver Diseases: Impact on Diagnosis & Management" of SEMINARS IN LIVER DISEASE today! https://t.co/xsmniVjC0G
🔹Spatial Biology, Research Tools
🔹Molecular Stratification
🔹MASLD, Viral Hepatitis, DILI & Hepatic Porphyria
@rabataller @DrPMonga
We're celebrating an increase of the impact factor for our @SeminLiverDis journal!
Enjoy free access to the most cited articles:
https://t.co/kuSsRlE5ei
https://t.co/aEhyW3s439
https://t.co/lXVaapSr1b
#liver#liverdisease#hepatology#gastroenterology
What is the New Nomenclature of NASH? Is it useful?
A must-read article on MASLD, MetALD and ALD nomenclature and its implications in clinical practice by @DrLoomba et al. in @SeminLiverDis!
https://t.co/8iSIcgVkSI
How and when should we detect liver fibrosis in PRIMARY CARE? Read this clear article by @MajaThiele et al. on current algorithms on early detection of liver disease in high risk groups in @SeminLiverDis! https://t.co/5yrf6hqcSn
Is Ursodeoxycholic Acid (UDCA) useful for drug-induced liver disease?
This great review by Fernando Bessone et al. reviews its mechanisms of action and clinical usefulness in @SeminLiverDis.
https://t.co/zjsAR5UfyZ
Issue 44.1 of SEMINARS IN LIVER DISEASE, "Metabolic-associated Steatotic Liver Disease (MASLD): a New Name for a New Era" out now! https://t.co/dKcdMYwJg0
🔹Liver Transplantation & Cancer
🔹Novel Targets for Therapy
🔹DILI; ALD; Fibrosis Algorithms
@DrPMonga @rabataller
Here you have the December 2023 issue of Seminars in Liver Disease. You can find great reviews on "Hot Topics in Basic and Clinical Hepatology: from Early Disease to HCC"
🔹Checkpoint inhibitors
🔹Steatosis
🔹Screening & ACLF
@DrPMonga @rabataller https://t.co/ebEIFW29Yd
Issue 42.4 of SEMINARS IN LIVER DISEASE, "NAFLD, Cirrhosis and HCC: from Basic Science to Clinical Outcomes," is out now! See link to issue here: https://t.co/6xdnjUcgND.
#LiverTwitter
Read this interesting review by Drs. Mohamed El-Kassas, @JCabezasGlez@PIruzubieta, et. al on “Non-alcoholic Fatty Liver Disease: Current Global Burden” in SLD: https://t.co/MSbCF8WsxO
#LiverTwitter
Check out this great review by @Nicholaswschew, @ChengHanNg, @NoureddinMD, @KowdleyMd and Dr. Emily Truong on “Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update” in SLD: https://t.co/K9zxj83gH8
#LiverTwitter